Search

Displaying results 5931 - 5940 of 10000 in total
  1. Drug

    Nelonicline

    go.drugbank.com/drugs/DB19040
    Investigational

    Nelonicline is under investigation in clinical trial NCT01678755 (A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia).

  2. Drug

    Eragidomide

    go.drugbank.com/drugs/DB19242
    Investigational

    Eragidomide is under investigation in clinical trial NCT04297124 (A Study to Evaluate the Metabolism and Excretion of [14C]-CC-90009 in Healthy Male Subjects).

  3. Drug

    MOR-22

    go.drugbank.com/drugs/DB17790
    Experimental

    MOR-22, a Natural human lymphoblastoid interferon-alpha, is currently being investigated to treat papillomavirus warts in the oral cavity of HIV-positive patients.

  4. Drug

    Jojoba oil

    go.drugbank.com/drugs/DB14252
    Approved

    Jojoba oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  5. Drug

    Scutellaria lateriflora

    go.drugbank.com/drugs/DB14339
    Approved

    Scutellaria lateriflora is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  6. Drug

    Cobitolimod

    go.drugbank.com/drugs/DB14819
    Investigational

    Cobitolimod is under investigation in clinical trial NCT03178669 (The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis).

  7. Drug

    KAHR-102

    go.drugbank.com/drugs/DB17427
    Investigational

    KAHR-102 is a dual signaling protein fusing cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to the Fas-ligand (FasL).

  8. Drug

    HMI-103

    go.drugbank.com/drugs/DB17684
    Investigational

    HMI-102 is an investigational gene therapy designed to encode the phenylalanine-4-hydroxylase (PAH) gene, mutated in people with phenylketonuria.

  9. Drug

    MYR-101

    go.drugbank.com/drugs/DB17075
    Investigational

    It is caused by a mutation in the aspartoacylase gene (_ASPA_), which leads to a deficiency of the aspartoacylase enzyme (ASPA). … [L43567] The FDA has granted MYR-101 Fast Track, Rare Pediatric Disease (RPD), and Orphan Drug designations for the treatment of patients with Canavan disease.[L43572]

  10. Drug

    GPI-1485

    go.drugbank.com/drugs/DB05814
    Investigational

    GPI 1485 is a product candidate that belongs to a class of small molecule compounds called neuroimmunophilin ligands. … In preclinical experiments, neuroimmunophilin ligands have been shown to repair and regenerate damaged nerves without affecting normal, healthy nerves.